Alpha Tau Medical Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DRTS research report →
Range $8 – $30
Price Chart
About the company
Alpha Tau Medical Ltd. , a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.
- CEO
- Uzi Sofer
- IPO
- 2021
- Employees
- 121
- HQ
- Jerusalem, JM, IL
Get TickerSpark's AI analysis on DRTS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.09B
- P/E
- -11.53
- Fwd P/E
- 12.99
- PEG
- 0.17
- P/S
- 0.00
- P/B
- 24.75
- EV/EBITDA
- -22.44
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -138.12%
- ROIC
- -40.04%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,232,000+0.0%
- Op Income
- $-42,288,000
- Net Income
- $-42,627,000-34.3%
- EPS
- $-0.53-17.8%
- OCF Growth
- -34.9%
- FCF Growth
- -48.7%
- 52W High
- $15.79
- 52W Low
- $3.43
- 50D MA
- $13.84
- 200D MA
- $11.01
- Beta
- 1.29
- RSI (14)
- 38
- Avg Volume
- 591.87K
No earnings-call transcripts are available for DRTS yet.
- Free Float
- 69.3%
- Shares Outstanding
- 92.48M
- Float Shares
- 64.10M
of shares held by institutions
80 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Gem Investment Advisors, LLC | 1.43M | 0 |
| Blackrock, Inc. | 1.40M | ▲ 1.39M |
| Ubs Group AG | 1.26M | ▲ 614.93K |
| Hightower Advisors, LLC | 894.04K | ▲ 19.05K |
| Boothbay Fund Management, LLC | 773.20K | ▼ 285 |
| Pier Capital, LLC | 730.21K | ▲ 38.27K |
| Aquamarine Financial (Cayman) Ltd | 721.50K | 0 |
| Citadel Advisors LLC | 577.18K | ▲ 515.62K |
| Polen Capital Management LLC | 216.35K | ▼ 4.40K |
| Mariner, LLC | 192.73K | ▲ 25.64K |
| Ark Investment Management LLC | 184.38K | ▼ 92.71K |
| Geode Capital Management, LLC | 150.92K | ▲ 97.52K |
Held by 47 ETFs
Biggest fund positions in DRTS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 21, 26 | Levy Raphi | other | 2,871 |
| Aug 21, 26 | Levy Raphi | sell | 2,871 |
| Aug 11, 26 | Levy Raphi | other | 17,730 |
| Aug 11, 26 | Levy Raphi | sell | 17,730 |
| Jul 6, 26 | Levy Raphi | other | 2,270 |
| Jul 6, 26 | Levy Raphi | sell | 2,270 |
| Jul 2, 26 | Levy Raphi | other | 17,873 |
| Jul 2, 26 | Levy Raphi | sell | 17,873 |
| Jul 1, 26 | Levy Raphi | other | 2,127 |
| Jul 1, 26 | Levy Raphi | sell | 2,127 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DRTS coverage
Recent articles, reports, and earnings notes.
No research on DRTS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DRTS report →Alpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Nov 19
Alpha Tau Medical: The Rubber Meets The Road In H1 2027
seekingalpha.com · Nov 18
Alpha Tau Medical Ltd. (DRTS) Discusses REGAIN Study Interim Results for Recurrent Glioblastoma Transcript
seekingalpha.com · Nov 16
Alpha Dart Therapy Shows Complete Tumor Clearance in Five Brain Cancer Patients
benzinga.com · Nov 16
Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16
globenewswire.com · Nov 15
Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial
globenewswire.com · Nov 12
Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange
globenewswire.com · Oct 29
Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea
globenewswire.com · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.